SPOTLIGHT: FDA reinstitutes Woodcock as CDER chief


The FDA is handing back the reins to the FDA's Center for Drug Evaluation and Research to Janet Woodcock, who had formerly headed the division for 10 years. The FDA described it as a "lateral move" for Woodcock, who will hang up her title as Deputy Commissioner for scientific and medical programs. CDER is a key part of the FDA. Its researchers are charged with evaluating the safety and efficacy of drugs, a role that has achieved heightened significance following a string of controversies over therapeutics that contained hidden threats. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.